Diabetes Care Devices Market - Growth, Trends, and Forecast (2019 - 2024)

The Global Diabetes Care Devices Market is segmented by Management Devices (Insulin Pumps, Insulin Pens, Syringes, Cartridges, and Jet Injectors) and Monitoring Devices (Self-monitoring Blood Glucose (Hospital and Personal use) and Continuous Glucose Monitoring), and Geography.

Market Snapshot

Diabetes Devices Market
Study Period:

2012-2024

Base Year:

2018

Fastest Growing Market:

North America

Largest Market:

North America

Key Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

  • The global diabetes care devices market is expected to register a CAGR of about 6.8% during the forecast period (2019-2024).
  • Asia-Pacific is anticipated to dominate the market during the forecast period, owing to the rising prevalence of obesity in the region.
  • There has been a significant rise in insulin delivery systems technology, from insulin injections to insulin pumps. 
  • Technological innovations and advances give much convenience in measuring the blood glucose levels. One such advancement in monitoring the blood glucose levels has established with continuous glucose monitoring devices.  

Scope of the Report

The Diabetes Care Devices Market is segmented by management devices (insulin pumps, insulin pens, syringes, cartridges, and jet injectors) and monitoring devices (self-monitoring blood glucose (hospital and personal use) and continuous glucose monitoring), and geography.

By Monitoring Devices Self-monitoring Blood Glucose Glucometer Devices Hospital
Personal
Blood Glucose Test Strips
Lancets
Continuous Glucose Monitoring Sensors  
Receivers  
By Management Devices Insulin Pump Insulin Pump Device  
Insulin Pump Reservoir  
Infusion Set  
Syringes Syringes  
Cartridges Cartridges  
Disposable Pens Disposable Pens  
Jet Injectors Jet Injectors  
By Region

 

North America

 

United States
Canada
Rest of North America

 
 
 
Europe

United Kingdom
Germany
France
Russia
Spain
Italy
Rest of Europe

 
 
 
 
 
 
 
Asia Pacific

Australia
China
India
Indonesia
Japan
Malaysia
Philippines
South Korea
Thailand
Vietnam
Rest of Asia Pacific

 
 
 
 
 
 
 
 
 
 
 
Latin America

Brazil
Mexico
Rest of Latin America

 
 
 
Middle East & Africa

Saudi Arabia
South Africa
Iran
Egypt
Oman
Rest of Middle East & Africa

 
 
 
 
 
 

Key Market Trends

Rising Prevalence of Diabetes

  • As per a WHO report, the global prevalence of diabetes among adults of over 18 years accelerated from about 4.7%, in 1980, to over 8.5%, in 2014.
  • Diabetes prevalence has been rising rapidly in the middle- and low-income countries. In 2015, about 1.6 million deaths were directly associated with diabetes, which was around 2.2 million in 2012.
  • Almost half of all deaths attributable to high blood glucose occur before the age of 70 years. WHO projects that diabetes is likely to be the seventh-leading cause of death by 2030.
  • Growing prevalence of diabetes is the major driver for the global diabetes care devices market. Additionally, rising awareness regarding diabetes care, growing prevalence of obesity, and technological advancements are further driving the market for diabetes care devices.
Diabetes Care Devices Market revenue

To understand key trends, Download Sample Report

North America to Dominate the Monitoring Devices Segment

  • The factors attributing to the North American market growth is the rising prevalence of diabetes, caused mainly due to urbanization and sedentary lifestyles.  
  • Asia-Pacific is anticipated to grow tremendously during the forecast period, owing to factors, such as a high prevalence of diabetes, growing obese population, and government initiatives of raising awareness regarding diabetic care.
Diabetes Devices Market share

To understand geography trends, Download Sample Report

Competitive Landscape

There have been constant innovations driven by manufacturers to compete and struggle in the market. The major players, such as Abbott and Medtronic, resort to inorganic market strategies, such as mergers and acquisitions, to establish market dominance, while also adhering to organic growth strategies, which is evident from the R&D spending of these companies. Examples of a few strategic outcomes include:

  • In March 2018, Medtronic PLC received the US Food and Drug Administration (FDA) approval for Guardian(TM) Connect continuous glucose monitoring (CGM) system, for people with diabetes aged between 14-75 years.
  • In January 2018, Abbott announced that the FreeStyleLibre System, the company's revolutionary new continuous glucose monitoring (CGM) system, was available to Medicare patients in the United States.

Major Players

  1. Abbott
  2. Dexcom
  3. Roche
  4. Becton Dickinson and Company
  5. Medtronic

* Complete list of players covered available in the table of contents below

Diabetes Care Device

Download the market shares of key players in this industry.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. Market Segmentation

    1. 5.1 Monitoring Devices

      1. 5.1.1 Self-Monitoring Blood Glucose Devices

        1. 5.1.1.1 By Component (Value and Volume, 2012 - 2024)

          1. 5.1.1.1.1 Glucometer Devices

          2. 5.1.1.1.2 Test Strips

          3. 5.1.1.1.3 Lancets

        2. 5.1.1.2 By End User

          1. 5.1.1.2.1 Hospital (Value and Volume, 2012 - 2024)

            1. 5.1.1.2.1.1 Glucometer Devices

            2. 5.1.1.2.1.2 Test Strips

            3. 5.1.1.2.1.3 Lancets

          2. 5.1.1.2.2 Personal (Value and Volume, 2012 - 2024)

            1. 5.1.1.2.2.1 Glucometer Devices

            2. 5.1.1.2.2.2 Test Strips

            3. 5.1.1.2.2.3 Lancets

      2. 5.1.2 Continuous Blood Glucose Monitoring

        1. 5.1.2.1 By Component (Value and Volume, 2012 - 2024)

          1. 5.1.2.1.1 Sensors

          2. 5.1.2.1.2 Receivers

    2. 5.2 Management Devices

      1. 5.2.1 Insulin Pump

        1. 5.2.1.1 Insulin Pump Device

        2. 5.2.1.2 Insulin Pump Reservoir

        3. 5.2.1.3 Infusion Set

      2. 5.2.2 Insulin Syringes

      3. 5.2.3 Insulin Cartridges

      4. 5.2.4 Disposable Pens

      5. 5.2.5 Jet Injectors

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States (Value and Volume, 2012 - 2024)

          1. 5.3.1.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.1.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.1.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

        2. 5.3.1.2 Canada (Value and Volume, 2012 - 2024)

          1. 5.3.1.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.1.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.1.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

        3. 5.3.1.3 Rest of North America (Value and Volume, 2012 - 2024)

          1. 5.3.1.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.1.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.1.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

      2. 5.3.2 Europe

        1. 5.3.2.1 France (Value and Volume, 2012 - 2024)

          1. 5.3.2.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.2.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.2.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

        2. 5.3.2.2 Germany (Value and Volume, 2012 - 2024)

          1. 5.3.2.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.2.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.2.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

        3. 5.3.2.3 Italy (Value and Volume, 2012 - 2024)

          1. 5.3.2.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.2.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.2.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

        4. 5.3.2.4 Spain (Value and Volume, 2012 - 2024)

          1. 5.3.2.4.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.2.4.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.2.4.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

        5. 5.3.2.5 United Kingdom (Value and Volume, 2012 - 2024)

          1. 5.3.2.5.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.2.5.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.2.5.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

        6. 5.3.2.6 Russia (Value and Volume, 2012 - 2024)

          1. 5.3.2.6.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.2.6.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.2.6.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

        7. 5.3.2.7 Rest of Europe (Value and Volume, 2012 - 2024)

          1. 5.3.2.7.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.2.7.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.2.7.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

      3. 5.3.3 Latin America

        1. 5.3.3.1 Mexico (Value and Volume, 2012 - 2024)

          1. 5.3.3.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.3.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.3.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

        2. 5.3.3.2 Brazil (Value and Volume, 2012 - 2024)

          1. 5.3.3.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.3.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.3.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

        3. 5.3.3.3 Rest of Latin America (Value and Volume, 2012 - 2024)

          1. 5.3.3.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.3.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.3.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

      4. 5.3.4 Asia-Pacific

        1. 5.3.4.1 Japan (Value and Volume, 2012 - 2024)

          1. 5.3.4.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.4.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.4.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

        2. 5.3.4.2 South Korea (Value and Volume, 2012 - 2024)

          1. 5.3.4.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.4.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.4.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

        3. 5.3.4.3 China (Value and Volume, 2012 - 2024)

          1. 5.3.4.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.4.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.4.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

        4. 5.3.4.4 India (Value and Volume, 2012 - 2024)

          1. 5.3.4.4.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.4.4.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.4.4.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

        5. 5.3.4.5 Australia (Value and Volume, 2012 - 2024)

          1. 5.3.4.5.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.4.5.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.4.5.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

        6. 5.3.4.6 Vietnam (Value and Volume, 2012 - 2024)

          1. 5.3.4.6.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.4.6.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.4.6.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

        7. 5.3.4.7 Malaysia (Value and Volume, 2012 - 2024)

          1. 5.3.4.7.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.4.7.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.4.7.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

        8. 5.3.4.8 Indonesia (Value and Volume, 2012 - 2024)

          1. 5.3.4.8.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.4.8.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.4.8.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

        9. 5.3.4.9 Philippines (Value and Volume, 2012 - 2024)

          1. 5.3.4.9.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.4.9.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.4.9.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

        10. 5.3.4.10 Thailand (Value and Volume, 2012 - 2024)

          1. 5.3.4.10.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.4.10.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.4.10.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

        11. 5.3.4.11 Rest of Asia-Pacific (Value and Volume, 2012 - 2024)

          1. 5.3.4.11.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.4.11.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.4.11.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

      5. 5.3.5 Middle East & Africa

        1. 5.3.5.1 Saudi Arabia (Value and Volume, 2012 - 2024)

          1. 5.3.5.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.5.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.5.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

        2. 5.3.5.2 Iran (Value and Volume, 2012 - 2024)

          1. 5.3.5.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.5.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.5.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

        3. 5.3.5.3 Egypt (Value and Volume, 2012 - 2024)

          1. 5.3.5.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.5.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.5.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

        4. 5.3.5.4 Oman (Value and Volume, 2012 - 2024)

          1. 5.3.5.4.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.5.4.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.5.4.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

        5. 5.3.5.5 South Africa (Value and Volume, 2012 - 2024)

          1. 5.3.5.5.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.5.5.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.5.5.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

        6. 5.3.5.6 Rest of Middle & Africa (Value and Volume, 2012 - 2024)

          1. 5.3.5.6.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.5.6.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

          3. 5.3.5.6.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)

  6. 6. MARKET INDICATORS

    1. 6.1 Type 1 Diabetes Population (2012-2024)

    2. 6.2 Type 2 Diabetes Population (2012-2024)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 COMPANY PROFILES

      1. 7.1.1 Abbott Diabetes Care

      2. 7.1.2 Roche

      3. 7.1.3 Johnson & Johnson

      4. 7.1.4 Dexcom

      5. 7.1.5 Medtronic

      6. 7.1.6 Arkray

      7. 7.1.7 Ascensia Diabetes Care

      8. 7.1.8 Agamatrix Inc.

      9. 7.1.9 Bionime Corporation

      10. 7.1.10 Acon

      11. 7.1.11 Medisana

      12. 7.1.12 Trivida

      13. 7.1.13 Rossmax

    2. 7.2 COMPANY SHARE ANALYSIS

      1. 7.2.1 Roche

      2. 7.2.2 Johnson & Johnson

      3. 7.2.3 Abbott Diabetes Care

      4. 7.2.4 Dexcom

      5. 7.2.5 Medtronics

      6. 7.2.6 Novo Nordisk

      7. 7.2.7 Eli Lilly

      8. 7.2.8 Sanofi

      9. 7.2.9 Others

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please Enter a Valid Message!


Complete your payment details below

Shipping & Billing Information

Payment Information